menu
    • menu
    [{"orgOrder":0,"company":"ARTBIO","sponsor":"FogPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ARTBIO","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ARTBIO \/ FogPharma","highestDevelopmentStatusID":"3","companyTruncated":"ARTBIO \/ FogPharma"},{"orgOrder":0,"company":"ARTBIO","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2023","type":"Financing","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"ARTBIO \/ F-Prime Capital","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ F-Prime Capital"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2023","type":"Series A Financing","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Intravenous Injection","sponsorNew":"ARTBIO \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ Third Rock Ventures"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2025","type":"Series B Financing","leadProduct":"212-Pb NG001","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"ARTBIO \/ Sofinnova Investments","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ Sofinnova Investments"}]

    Find Clinical Drug Pipeline Developments & Deals by ARTBIO

    Menu

    ARTBIO

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ARTBIO

                            Norway arrow
                            AGGSpend
                            Not Confirmed

                            ARTBIO

                            Norway arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb NG001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Sofinnova Investments

                            Deal Size : $132.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Artbio Raises $132M Series B to Advance Alpha Radioligand Therapy Pipeline

                            Details : The financing aims to fund the clinical development of AB001 (212-Pb-NG001), which is being evaluated for the treatment of metastatic castration-resistant prostate cancer.

                            Product Name : AB001

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            July 29, 2025

                            Lead Product(s) : 212-Pb NG001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Sofinnova Investments

                            Deal Size : $132.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ARTBIO

                            Norway arrow
                            AGGSpend
                            Not Confirmed

                            ARTBIO

                            Norway arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : FogPharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            FogPharma and ARTBIO Collaborate on Alpha-Particle Radioligand Therapies

                            Details : The collaboration aims to co-develop Helicon-enabled 212Pb alpha radioligand therapies by leveraging FogPharma’s field-leading Helicon platform and ARTBIO’s AlphaDirect™ platform, for cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : FogPharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ARTBIO

                            Norway arrow
                            AGGSpend
                            Not Confirmed

                            ARTBIO

                            Norway arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb NG001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Third Rock Ventures

                            Deal Size : $90.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Techn...

                            Details : The proceeds will be used to help solidify ARTBIO's proprietary Pb212 isolation technology AlphaDirect™ and its distributed manufacturing network, advance its lead program AB001 (212Pb-NG001) in the clinic for treatment of prostate cancer, and further ...

                            Product Name : AB001

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            July 12, 2023

                            Lead Product(s) : 212-Pb NG001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Third Rock Ventures

                            Deal Size : $90.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ARTBIO

                            Norway arrow
                            AGGSpend
                            Not Confirmed

                            ARTBIO

                            Norway arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb NG001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : F-Prime Capital

                            Deal Size : $23.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential

                            Details : The financing enables ARTBIO's ongoing clinical development of its lead program AB001 (212Pb-NG001) for the treatment of prostate cancer and will advance its AlphaDirect™ Pb212 isolation technology.

                            Product Name : AB001

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            June 21, 2023

                            Lead Product(s) : 212-Pb NG001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : F-Prime Capital

                            Deal Size : $23.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth